Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Derek Jantz , Ph.D., Chief Scientific
Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, issued the following statement about the safety of its allogeneic CAR T cell therapies.
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced an inducement grant for Michael Amoroso , newly
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced that Michael Amoroso has been named as the
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will present at the H.C.
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
- Accelerated Clinical Development Expected to Enable Three Investigational New Drug/Clinical Trial Applications Within Next Three Years, Including for Familial Hypercholesterolemia as early as 2022, Primary Hyperoxaluria Type 1 in 2023, and Chronic Hepatitis B in 2024 - Announced Licensing and
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
iECURE to License Precision’s PCSK9-Directed ARCUS Nuclease and Pursue Four Gene Insertion Programs Focused on Liver Diseases; Precision Retains Rights Across All Indications Except Those Licensed to iECURE iECURE Expects to File a Clinical Trial Application as Early as 2022 for Precision’s
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Precision Gains Access to Tiziana’s Anti-CD3 Antibody, Foralumab, to Evaluate as a Lymphodepletion Agent with its Allogeneic CAR T Portfolio DURHAM, N.C. , NEW YORK & LONDON --(BUSINESS WIRE)--Sep. 2, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 25, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will host its first R&D event focused
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
- Presented Interim Data Showing PBCAR0191 with Enhanced Lymphodepletion Yielded Overall Response Rate of 75% and Complete Response Rate of 50% at Day ≥ 28 - Dosed First Patient in CD19-Targeted Phase 1 Clinical Trial with PBCAR19B Immune-Evading Stealth Cell - Precision to Host First In Vivo Gene
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Aug. 5, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that it will publish financial results for the
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
DURHAM, N.C. --(BUSINESS WIRE)--Jul. 1, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that the first patient has been dosed in its
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
DURHAM, N.C. & STAMFORD, Conn. --(BUSINESS WIRE)--Jun. 28, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc.
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells Following Enhanced Lymphodepletion (eLD) - Median Interval of 1 Day from Enrollment to Start of Lymphodepletion - Single Dose of PBCAR0191 with eLD Yielded Overall